New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
12:06 EDTCHRW, NVS, SFLY, BPI, BBEPHigh option volume stocks: BBEP SFLY CHRW BPI NVS
News For BBEP;SFLY;CHRW;BPI;NVS From The Last 14 Days
Check below for free stories on BBEP;SFLY;CHRW;BPI;NVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2014
05:29 EDTNVSNovartis divests Animal Health Division to Eli Lilly for about $5.4B
Subscribe for More Information
05:26 EDTNVSNovartis OTC, GSK Consumer Healthcare form joint venture
Subscribe for More Information
05:23 EDTNVSNovartis divests Vaccines business to GSK for $7.1B
Novartis (NVS) has agreed to divest its Vaccines business to GSK (GSK), currently excluding its flu business, for $7.1B plus royalties. The $7.1B consists of $5.25B upfront and up to $1.8B in milestones. As a part of a value-maximization strategy in the context of the portfolio review, Novartis has initiated a separate sales process for its flu business.
05:20 EDTNVSNovartis to acquire GSK oncology products for $14.5B
Subscribe for More Information
April 21, 2014
08:18 EDTNVSMomenta Pharma rises after high court rejects Copaxone delay bid
Shares of Momenta Pharmaceuticals (MNTA) are higher in pre-market trading after the Supreme Court denied Teva's (TEVA) request to delay the launch of generic forms of its relapsing-remitting multiple sclerosis product, Copaxone. WHAT'S NEW: Teva confirmed on April 19 that the Chief Justice of the United States denied the company's application for an injunction seeking to prevent the launch of a generic version of Copaxone. Teva will continue pursuing its appeal in the Supreme Court and defending its intellectual property for Copaxone, the company said. WHAT'S NOTABLE: Momenta has developed a generic version of Copaxone in partnership with Novartis' (NVS) Sandoz unit. Mylan, which is preparing to launch a generic version of Copaxone as well, said after the ruling: "We are pleased with the Chief Justice's decision, and we look forward to introducing the first generic Copaxone treatment for multiple sclerosis patients in the U.S. at market formation. Mylan remains eligible to receive approval from the U.S. FDA on May 25, 2014." PRICE ACTION: In pre-market trading, Momenta shares are up over 12% to $12.46, while Mylan shares are up more than 3% to $48.48. Teva shares trading in New York are down about 1.7% to $50 in pre-market trading.
07:21 EDTNVSFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 16, 2014
13:51 EDTNVSAlnylam COO critical of big pharma, FierceDrugDelivery reports
After Novartis (NVS) decided to end its RNAi research, Alnylam COO Barry Greene told FierceDrugDelivery that big pharma has "never been able to innovate." Greene attributes the recent sell-off in Alnylam shares to "generally bearish sentiment on Wall Street regarding biotech stocks in particular." Reference Link
11:19 EDTNVSNovartis launches new eye care products facility in Singapore, Nikkei says
Subscribe for More Information
April 15, 2014
07:35 EDTNVSAlnylam outlook not affected by Novartis decision, says JMP Securities
Subscribe for More Information
07:22 EDTNVSNovartis to Shire said to mull offers for ThromboGenics, Bloomberg says
Subscribe for More Information
06:36 EDTNVSRanbaxy inspection failures add $900M to heart drug costs, Bloomberg says
A gap in U.S. patent law has kept cheap copies of Novartis' (NVS) heart drug Diovan off the market for 18 months, which has cost U.S. consumers and insurers as much as $900M in possible savings, reported Bloomberg. Ranbaxy (RBXLY) is the only company permitted to sell a generic version of Diovan, and hasnít been able to manufacture and market them after four factories it runs in India failed U.S. inspections. Reference Link
06:32 EDTNVSPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
15:29 EDTCHRWC.H. Robinson May volatility elevated at 29 on sharp three-day rally
Subscribe for More Information
14:42 EDTNVSAlnylam slips after Novartis reportedly cuts back RNAi development
Subscribe for More Information
11:48 EDTNVSNovartis significantly reducing RNAi development efforts, FierceBiotech says
Subscribe for More Information
April 11, 2014
12:42 EDTCHRW, SFLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:00 EDTSFLYShutterfly rises 3.2%
Subscribe for More Information
07:53 EDTCHRWC.H. Robinson upgraded to Buy from Hold at BB&T
06:20 EDTSFLYShutterfly upgraded to Buy from Neutral at Goldman
Subscribe for More Information
April 10, 2014
09:20 EDTCHRWC.H. Robinson margins improving, says Cleveland Research
Cleveland Research's checks indicate C.H. Robinson's margins have improved due to increased volumes of spot/transactional freight and shippers accepting rate increases. The firm remains slightly below consensus for Q1 earnings estimates and slightly above consensus for Q2.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use